Raf Kinase Inhibitor Protein Expression and Prognostic Value in Soft Tissue Sarcomas

Pathobiology. 2016;83(1):41-6. doi: 10.1159/000441227. Epub 2016 Feb 10.

Abstract

Objective: Soft tissue sarcomas (STSs) are heterogeneous tumors displaying multiple and complex molecular abnormalities with no specific pattern. Despite current therapeutic advances, the patients with STS still have a poor outcome, which makes it necessary to find out new prognostic markers. The Raf kinase inhibitory protein (RKIP) has been associated with prognosis in several human neoplasms; however, its role in STS is unknown.

Methods: In the present study RKIP expression was assessed by immunohistochemistry in a series of 87 STSs, and its expression profile was associated with the patients' pathological parameters.

Results: We found that RKIP is expressed in the cytoplasm of the great majority of cases, and absent in only approximately 18% of cases (16/87). Importantly, we observed that loss of RKIP expression was associated with poor outcome, constituting an independent prognostic marker.

Conclusion: This is the first study assessing RKIP expression levels in STS. We showed that loss of RKIP expression is present in a small subset of cases; however, its absence was associated with poor survival and may be a potential marker for STS prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Phosphatidylethanolamine Binding Protein / genetics*
  • Prognosis
  • Sarcoma / diagnosis*
  • Sarcoma / genetics*
  • Sarcoma / pathology
  • Sarcoma / ultrastructure
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • PEBP1 protein, human
  • Phosphatidylethanolamine Binding Protein